Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey
Kerry Skurka(Franciscan Health Indianapolis), Lavanya Kondapalli(Moffitt Cancer Center), Sebastian Szmit, Arjun K. Ghosh(University College Hospital), Luis E. Raez(Florida International University), Lauren A. Baldassarre(Yale University), Monika Leja(University of Michigan), Vlad G. Zaha(Southwestern Medical Center), Jorge A. Lax(University of Minnesota), Zeina Nahleh(Cleveland Clinic Florida), Sherry‐Ann Brown(Florida International University), Anne Blaes(University of Minnesota), Husam Abdel‐Qadir(University Health Network), Andrés J. Daniele(Asociación por los Derechos Civiles), J. Raikhelkar(NewYork–Presbyterian Hospital), Susan Dent(Government of the United States of America), Leah Elson(Yale University), Brenton Bauer(Torrance Memorial Medical Center), Eric H. Yang(University of California, Los Angeles), Jeanne M. DeCara(University of Chicago), Anita Arnold(St Bartholomew's Hospital), Roohi Ismail-Khan(Argerich Hospital), Daniel Sierra Lara(Franciscan Health Indianapolis), Franck Thuny(Assistance Publique Hôpitaux de Marseille), Diego Sadler(University of Chicago), Nausheen Akhter, Joerg Herrmann(Mayo Clinic), Rupal O’Quinn(Penn Presbyterian Medical Center), Tochukwu Okwuosa(Rush University Medical Center), Carolina Maria Pinto Domingues Carv Silva(Universidade de São Paulo), Rohit Moudgil(Cleveland Clinic), Vijay Rao(Franciscan Health Indianapolis)
Cited by 28
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642